ZIOPHARM is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.
(Nasdaq:ZIOP)
(Nasdaq:ZIOP)
Location: United States, Massachusetts, Boston
Investors 3
| Date | Name | Website |
| 14.05.2021 | EW Healthc... | ewhealthca... |
| - | Emerging T... | etpvc.com |
| - | Cycad Grou... | cycadvc.co... |
Mentions in press and media 17
| Date | Title | Description |
| 03.06.2025 | Dimension Bio Appoints Biotech Veteran Heidi Hagen to Board of Directors | Heidi Hagen Dimension Bio appoints biotechnology veteran Heidi Hagen to its Board of Directors, bringing decades of cell therapy leadership as the company advances its liver failure program toward the clinic. CHICAGO, June 3, 2025 /PRNewswi... |
| 26.02.2021 | NK cell therapy player Artiva makes some more noise, pulling in $120M Series B less than a month after Merck deal | Not even one month after Big Pharma took notice of Artiva when Merck signed a collaboration worth nearly $2 billion in milestones, the off-the-shelf NK cell biotech already has its next big fundraise. Artiva returns from the ... |
| 26.02.2021 | Gossamer pushes ahead with failed asthma drug; Cullgen gets $50M Series B for protein degraders | After getting beaten up by investors over the key failure of its lead drug GB001, Gossamer had already indicated that they thought they could move ahead in asthma, though likely through a partnership. And the biotech is pushi... |
| 26.02.2021 | J&J adcomm live blog: Committee votes 22-0 to recommend an FDA OK for the J&J vaccine, setting up 3rd US Covid-19 jab | The US could have a third authorized Covid-19 vaccine within hours. The FDA’s advisory committee voted unanimously — 22-0 — to recommend the agency issue an emergency use authorization for J&J’s vaccine. If they fol... |
| 26.02.2021 | Perceptive's fourth — yes, fourth — SPAC jumps to Nasdaq as the blank check tree continues to ripen | The biotech SPAC boom has gone almost hand-in-hand with the industry’s IPO gold rush, and this week saw more blank check companies hop aboard the train. James Huang Leading the way is Perceptive Advisors’ fourth SPAC, appropria... |
| 26.02.2021 | Mark Mallon charts post-Ironwood course by taking CEO job at NeoGenomics; GlaxoSmithKline vet Feng Ren joins Insilico as CSO | Mark Mallon → Mark Mallon steps aside at Ironwood on March 12 after close to two years at the helm, and he already has a new change of scenery squared away. Beginning April 19, Mallon takes charge as CEO of cancer-focused geneti... |
| 26.02.2021 | The path to NASH: understanding the role of severe obesity in a complex, multi-system disease | Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship a... |
| 26.02.2021 | Genentech plots $53M discovery quest aimed at sparking a 'Holy moly' pivot in neuro R&D | New Roivant CEO Matt Gline has crafted an all-equity upfront deal to buy out a Boston-based biotech that has been toiling for several years now at building a supercomputing-based computational platform to design new drugs. And he’s adding i... |
| 25.02.2021 | Follow biotechs going public with the Endpoints News IPO Tracker | Sarepta may be running into some trouble with its next-gen gene therapy approach to Duchenne muscular dystrophy. But when it comes to antisense oligonucleotides, the well-trodden regulatory path is still leading straight to an accelerated a... |
| 25.02.2021 | Follow biotechs going public with the Endpoints News IPO Tracker | A couple weeks after racking up its third EUA for a Covid-19 treatment — this one for its antibody cocktail — Eli Lilly has struck a deal with the US government for at least 100,000 doses. The US will pay $210 million for doses of bamlanivi... |
Show more